In its latest quarterly disclosure, Zhengye Biotechnology Holding Ltd approved critical governance changes, including share reclassification and adoption of new corporate articles, signaling a strategic alignment to enhance compliance and shareholder confidence. The veterinary vaccine producer faces a challenging 2025 marked by revenue declines driven by livestock market volatility and regulatory constraints, compounded by internal controls weaknesses. Zhengye’s business relies heavily on livestock vaccine sales backed by research collaborations, but customer concentration and demand fluctuations present growth challenges. Ongoing R&D investment and steps to remediate governance issues set the stage for potential recovery in operational stability.